"Close legal loophole" for circumventing diagnostics PMAs (premarket approvals)
This article was originally published in Clinica
Executive Summary
A well-known FDA lawyer has asked the agency to wield its warning letter authority to stop certain diagnostic manufacturers from abusing a regulatory loophole in order to avoid having to go through the agency's premarket review process.